Cure My Disease

Don't miss your cure!

 Log in / Sign up

Biopsy DNA clues could spare esophageal cancer patients from futile chemo

NCT ID NCT06490003

Knowledge-focused Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study investigates whether DNA methylation patterns in tumor biopsy samples can predict how well esophageal cancer patients will respond to chemotherapy. Researchers aim to develop a model that identifies patients unlikely to benefit from standard chemo drugs like Fluorouracil and Cisplatin. The study enrolls 150 adults with esophageal squamous cell carcinoma who are receiving their first round of chemotherapy. If the model works, it could help personalize treatment and avoid ineffective therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fluoro Uracil (Cisplatin)
What this could lead to
If successful, this could help doctors quickly identify which esophageal cancer patients won't benefit from standard chemotherapy, allowing them to explore alternative treatments sooner.
What could go wrong
This is an early-stage model development study with 150 participants. The DNA methylation prediction method may not prove accurate enough for clinical use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2004

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Chemotherapy naive patient needed esophageal squamous cell carcinoma chemotherapy

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients who had histologically confirmed esophageal squamous cell carcinoma. 2. Patients who had undergone chemotherapy. 3. Patients receiving initial chemotherapy 4. Written informed consent following full study information is provided to the patient. Exclusion Criteria: 1. Patients for whom a preoperative biopsy sample cannot be obtained 2. Patients who cannot assess at 2 months later after chemotherapy. 3. Patients with multiple cancers.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy effect are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced toxicity esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy effect DNA methylation Esophageal squamous cell carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Yamanashi Universiy

    RECRUITING

    Chūō, Yamanashi, 4093898, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.